Group 1: Investment Insights - Johnson & Johnson (NYSE:JNJ) is considered a strong long-term low volatility stock for investment, with BofA raising the price target to $227 from $221 while maintaining a Neutral rating [1] - The increased price target reflects a higher blended P/E multiple, assuming raised MedTech and Pharma multiples along with higher organic growth due to a defensive premium [1] Group 2: Product Developments - Johnson & Johnson announced FDA approval for DARZALEX FASPRO® in combination with bortezomib, lenalidomide, and dexamethasone for treating adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant [3] - This approval marks the twelfth indication for DARZALEX FASPRO® and the fifth in the newly diagnosed setting, emphasizing its foundational role in treating both newly diagnosed and relapsed/refractory multiple myeloma patients [4] Group 3: Legal Considerations - A Daubert ruling in the talc MDL case is expected within the next 1-2 months, although the outcome of legal cases is inherently unpredictable [2] - BofA believes the talc risk is manageable, estimating that even a mid-teens billion resolution cost would be less than 3% of the company's market cap [2] Group 4: Company Overview - Johnson & Johnson operates through two segments: Innovative Medicine and MedTech, focusing on various therapeutic areas including oncology, infectious diseases, immunology, and cardiovascular diseases [5] - The MedTech segment includes a wide range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields [5]

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to invest in. Eli Lilly and Company (NYSE:LLY) announced on January 30 significant plans to invest over $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania, which would function as the company’s newest injectable medicine and device manufacturing facility, producing next-generation weight-loss therapies. These include retatrutide, a first-in-class investigational GIP, GLP-1, and glucagon triple h ...

吉林长龙药业(08049)发布公告，于2026年2月3日，本公司向中国工商银行认购结构性存款产品，金额 人民币1亿元。 ...

Core Insights - The Penicillin Drug Market is projected to grow from USD 11.39 billion in 2026 to USD 13.23 billion by 2031, with a CAGR of 3.05% during the forecast period [1] - The market reflects the maturity of penicillin as a foundational antibiotic while presenting new opportunities through b-lactamase-inhibitor innovations and rising demand for narrow-spectrum agents [2] Market Dynamics - Increasing drug-resistant gram-positive infections are driving demand for narrow-spectrum penicillins, with healthcare systems facing a rise in methicillin-resistant Staphylococcus and carbapenem-resistant Acinetobacter strains [4] - Manufacturers are localizing supply chains to mitigate risks associated with Chinese API concentration, while hospitals are tightening formulary controls around first-line agents [3] - Online pharmacies are capturing incremental retail volumes, contributing to the market's resilient growth despite broader antibiotic volumes plateauing [3] R&D and Innovation - There is an accelerated investment in R&D for b-lactamase-inhibitor combinations, enhancing penicillin effectiveness against resistant strains [6] - The U.S. FDA approved sulbactam-durlobactam for Acinetobacter infections in 2023, showcasing lower nephrotoxicity compared to colistin [6] - Innovations like the DUPLEX container for piperacillin-tazobactam are reducing preparation time and contamination risks, supporting premium pricing for advanced semisynthetic penicillins [6] Segment Analysis - Natural penicillins held a 53.10% market share in 2025, remaining essential for treating streptococcal and syphilitic infections [8] - Semisynthetic penicillins are growing at a 6.35% CAGR, driven by rising resistance patterns and hospital demand for broader coverage [9] - Oral preparations accounted for 41.05% of the market in 2025, advancing at a 5.85% CAGR due to outpatient care models and higher patient adherence [11] Geographic Insights - North America captured 37.20% of the market share in 2025, supported by sophisticated reimbursement systems and robust antimicrobial stewardship [14] - Europe is enhancing its antibiotic modernization efforts, with significant investments like Sandoz's EUR 200 million upgrade to its production hub [15] - Asia Pacific is experiencing the fastest growth at a 5.05% CAGR, driven by India's PLI-funded penicillin G restart and China's increasing domestic demand [16]

Geopolitical and Energy Sector Developments - U.S. aircraft carrier "Abraham Lincoln" is positioned near the Gulf of Aden, highlighting ongoing regional tensions [3] - Kuwait Petroleum Corporation (KPC) plans to invite international oil companies to assist Kuwait Oil Company (KOC) in resource development, targeting an increase to four million barrels of oil per day by 2035 [4] Corporate News: Buybacks and Regulatory Hurdles - Fuji Media Holdings Inc. has initiated a 235 billion yen share buyback program amid reports of activist investors divesting their shares [5] - AstraZeneca faced a setback as the FDA rejected its initial application for a lupus injection, potentially impacting its drug pipeline and market expectations [6] Commodity Market Dynamics - Spot silver prices surged over 9% to reach $86.58 per ounce, indicating significant activity in the precious metals market [7] - The Shanghai Gold Exchange announced increased margin ratios and price limits for some gold contracts to manage volatility in the precious metals market [8] European Economic Indicators - France's December budget balance improved to -124.7 billion EUR from -155.4 billion EUR, indicating a reduction in the fiscal deficit [9][10] - Preliminary figures for France's January Consumer Price Index (CPI) showed a deceleration to 0.3%, missing estimates [10]

Core Viewpoint - The company is collaborating with the U.S. regulator to advance an updated application, with a decision anticipated in the first half of 2026 [1] Group 1 - The company is working with the U.S. regulator to move forward with an updated application [1] - A decision regarding the application is expected in the first half of 2026 [1]

AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an easier-to-use version of lupus therapy Saphnelo, pushing back the timeline for a possible approval to the... ...

Group 1 - Orion Corporation has converted 62,752 A shares into B shares, which has been officially recorded in the Trade Register on February 3, 2026 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,524,740 A shares and 109,609,538 B shares [1] - The total number of votes associated with the company's shares after the conversion is 740,104,338 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

3 February 2026 News Release Pharma Equity Group2026 Financial Calendar ​March 4Deadline for shareholder proposals - Annual General meeting​ ​March 18 ​Annual Report 2025​ April 16Annual General Meeting​ August 14Interim Report – for the six-month period ended June 30. 2026​ ​Contact person – Investor Relations On the Company’s website www.pharmaequitygroup.com further information and all published announcements can be found. Inquiries regarding relations with investors and the stock market can be directe ...

Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of the drug Fluorobiphenyl Patch [1] - The product is designed with a controlled-release membrane, featuring a large drug load, low irritation, and reduced risk of skin allergies, making it suitable for chronic pain conditions [2] - The original research product has not yet been launched in the domestic market and is classified as a Class 3 chemical drug [1] Group 2 - The approval of this clinical trial is expected to enhance the company's product portfolio in the musculoskeletal field, complementing its core products and improving its "internal + external" orthopedic solutions [3] - The market for similar products, such as Fluorobiphenyl Gel Patch, is significant, with sales reaching 2.839 billion yuan in 2024 and 2.350 billion yuan in the first three quarters of 2025 [2]